AR008071A1 - Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen - Google Patents
Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienenInfo
- Publication number
- AR008071A1 AR008071A1 ARP970103330A ARP970103330A AR008071A1 AR 008071 A1 AR008071 A1 AR 008071A1 AR P970103330 A ARP970103330 A AR P970103330A AR P970103330 A ARP970103330 A AR P970103330A AR 008071 A1 AR008071 A1 AR 008071A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- straight
- composition
- lower alkyl
- branched chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Abarca los compuestos de la fórmula (I), en la cual uno de los X1, X2 y X3 es fórmula (II), y el resto de los miembros del grupo X1, X2 y X3 sonhidrógeno; y Q es nitrógeno u oxígeno; D está ausente cuando Q es oxígeno y cuando Q es nitrógeno, Des hidrógeno, alquilo inferior de cadena recta oramificada con 1 a 6 átomos de carbono, o puede estar unido con G para formar un anillo; E es O o H2; o y r son 0 o 1; G es alquilo inferior de cadenarecta o ramificada con 1 a 6 átomos de carbono, arilo, arilo sustituido con halógeno, alquilo inferior de cadena recta o ramificada con 1 a 6 átomos decarbono, heteroarilo seleccionado entre el grupo que consiste en 2-, 3- o 4- piridilo, 2-pirazilo, 2- o 3-tienilo, 2-pirazinilo, 2-, 3- o 4-quinolilo, 1-,3- o 4-isoquinolilo, 2-quinoxalilo, 3- o 4-cinolilo, heteroarilo sustituido con halógeno, hidroxi, alquilo inferior de cadena recta o ramificada con 1 a 6átomos de carbono, alcoxi inferior de cadena recta o ramificada con 1 a 6átomos de carbono; o está unido a D para formar un anillo; Ar es un grupoarilo preferentemente seleccionado entre el grupo que consiste en fenilo, 2- 3- o 4-piridilo, 2- o 3-tienilo, 2-, 4- o 5-pirimidilo, cada uno de los cualeses optativamente mono- o disustituido con halógeno, hidroxi, o alquilo inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; B es azufre,oxígeno, N(R5) o C(R5)(R6); n es 1, 2 o 3; m es 2, 3 o 4; A y T son iguales o diferentes y representan hidrógeno, halógeno, hidroxi, alquilo inferior decadena recta o ramificada con 1 a 6 átomos de carbono, o alcoxi inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; R1 y R2 son igualeso diferentes y representan hidrógeno, o alquilo inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; R3 y R4 son iguales o diferentes y
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2229896P | 1996-07-23 | 1996-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008071A1 true AR008071A1 (es) | 1999-12-09 |
Family
ID=21808875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970103330A AR008071A1 (es) | 1996-07-23 | 1997-07-23 | Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6133265A (es) |
| EP (1) | EP0918761B1 (es) |
| JP (1) | JP2000515527A (es) |
| AR (1) | AR008071A1 (es) |
| AT (1) | ATE239002T1 (es) |
| AU (1) | AU3671897A (es) |
| CA (1) | CA2260983A1 (es) |
| CO (1) | CO4890841A1 (es) |
| DE (1) | DE69721541T2 (es) |
| DK (1) | DK0918761T3 (es) |
| ES (1) | ES2197354T3 (es) |
| HR (1) | HRP970412A2 (es) |
| ID (1) | ID17453A (es) |
| MA (1) | MA26435A1 (es) |
| PA (1) | PA8434601A1 (es) |
| PE (1) | PE1999A1 (es) |
| PT (1) | PT918761E (es) |
| TN (1) | TNSN97127A1 (es) |
| WO (1) | WO1998003494A1 (es) |
| ZA (1) | ZA976470B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2197354T3 (es) * | 1996-07-23 | 2004-01-01 | Neurogen Corporation | Derivados de bencilamina sustituidos con amido y amino; una nueva clase de ligandos especificos del neuropeptido y1. |
| SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| EP1033366A3 (en) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
| AU783403B2 (en) * | 2000-07-05 | 2005-10-20 | H. Lundbeck A/S | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
| MXPA03000174A (es) | 2000-07-06 | 2003-09-22 | Neurogen Corp | Ligandos de receptor de hormona concentradora de melanina. |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
| US7514438B2 (en) | 2003-08-13 | 2009-04-07 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
| WO2005049027A2 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| CA2554809C (en) | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CA2571949C (en) | 2004-06-24 | 2015-05-12 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| AU2006331614A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of ABC transporters |
| HUE049976T2 (hu) | 2005-12-28 | 2020-11-30 | Vertex Pharma | N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói |
| US7674811B2 (en) | 2006-03-14 | 2010-03-09 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
| ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
| EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| EA022420B1 (ru) | 2010-03-10 | 2015-12-30 | Пробиодруг Аг | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
| JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US11130743B2 (en) | 2019-02-21 | 2021-09-28 | Marquette University | Heterocyclic ligands of PAR1 and methods of use |
| WO2020172609A1 (en) * | 2019-02-21 | 2020-08-27 | Marquette University | Heterocyclic ligands of par1 and methods of use |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
| DE69033100T2 (de) * | 1989-04-22 | 2000-01-05 | John Wyeth & Brother Ltd., Maidenhead | Piperazin-Derivate |
| US5900415A (en) * | 1994-11-07 | 1999-05-04 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
| IL117997A0 (en) * | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
| WO1998003493A1 (en) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
| US5962455A (en) * | 1996-07-23 | 1999-10-05 | Neurogen Corporation | Certain substituted benzylamine derivatives a new class of neuropeptide Y1 specific ligands |
| ES2197354T3 (es) * | 1996-07-23 | 2004-01-01 | Neurogen Corporation | Derivados de bencilamina sustituidos con amido y amino; una nueva clase de ligandos especificos del neuropeptido y1. |
-
1997
- 1997-07-18 ES ES97933564T patent/ES2197354T3/es not_active Expired - Lifetime
- 1997-07-18 EP EP97933564A patent/EP0918761B1/en not_active Expired - Lifetime
- 1997-07-18 AU AU36718/97A patent/AU3671897A/en not_active Abandoned
- 1997-07-18 AT AT97933564T patent/ATE239002T1/de not_active IP Right Cessation
- 1997-07-18 PT PT97933564T patent/PT918761E/pt unknown
- 1997-07-18 CA CA002260983A patent/CA2260983A1/en not_active Abandoned
- 1997-07-18 WO PCT/US1997/012690 patent/WO1998003494A1/en active IP Right Grant
- 1997-07-18 DE DE69721541T patent/DE69721541T2/de not_active Expired - Fee Related
- 1997-07-18 JP JP10507143A patent/JP2000515527A/ja not_active Ceased
- 1997-07-18 DK DK97933564T patent/DK0918761T3/da active
- 1997-07-18 US US08/897,046 patent/US6133265A/en not_active Expired - Fee Related
- 1997-07-21 TN TNTNSN97127A patent/TNSN97127A1/fr unknown
- 1997-07-22 ZA ZA976470A patent/ZA976470B/xx unknown
- 1997-07-22 MA MA24730A patent/MA26435A1/fr unknown
- 1997-07-22 PE PE1997000652A patent/PE1999A1/es not_active Application Discontinuation
- 1997-07-23 ID IDP972554A patent/ID17453A/id unknown
- 1997-07-23 HR HR60/022,298A patent/HRP970412A2/hr not_active Application Discontinuation
- 1997-07-23 PA PA19978434601A patent/PA8434601A1/es unknown
- 1997-07-23 AR ARP970103330A patent/AR008071A1/es unknown
- 1997-07-23 CO CO97041974A patent/CO4890841A1/es unknown
-
2000
- 2000-08-08 US US09/633,055 patent/US6316617B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA976470B (en) | 1998-08-04 |
| MA26435A1 (fr) | 2004-12-20 |
| DE69721541D1 (de) | 2003-06-05 |
| EP0918761A1 (en) | 1999-06-02 |
| US6133265A (en) | 2000-10-17 |
| EP0918761B1 (en) | 2003-05-02 |
| ES2197354T3 (es) | 2004-01-01 |
| WO1998003494A1 (en) | 1998-01-29 |
| DE69721541T2 (de) | 2004-03-18 |
| PE1999A1 (es) | 1999-02-02 |
| CO4890841A1 (es) | 2000-02-28 |
| ATE239002T1 (de) | 2003-05-15 |
| CA2260983A1 (en) | 1998-01-29 |
| AU3671897A (en) | 1998-02-10 |
| TNSN97127A1 (fr) | 2005-03-15 |
| DK0918761T3 (da) | 2003-08-25 |
| JP2000515527A (ja) | 2000-11-21 |
| PA8434601A1 (es) | 2000-05-24 |
| US6316617B1 (en) | 2001-11-13 |
| PT918761E (pt) | 2003-09-30 |
| HRP970412A2 (en) | 1998-10-31 |
| ID17453A (id) | 1998-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008071A1 (es) | Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen | |
| HUP0104188A2 (hu) | Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként | |
| DK0468470T3 (da) | Benzimidazoler, lægemidler indeholdende sådanne forbindelser og fremgangsmåde til deres fremstilling | |
| HUP0301382A2 (hu) | Alfa-aril-etanol-amin-származékok és e vegyületeket tartalmazó béta-3 adrenergiás receptor agonista hatású gyógyászati készítmények | |
| HUP0100819A2 (hu) | Aminofenoxiecetsavszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
| ATE175962T1 (de) | Anilin derivate | |
| AR028531A1 (es) | Compuestos organicos | |
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| TR200002671T2 (tr) | Bisiklo(2.2.1)Heptanlar ve ilgili bileşikler | |
| MXPA03011324A (es) | Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa. | |
| HUP0203323A2 (hu) | Tirozin kináz inhibitorok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
| AR013184A1 (es) | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| HUP0302468A2 (hu) | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
| CY1115643T1 (el) | Διεγερτης νευρογενεσης ή θεραπευτικος παραγων νευροπαθειας που περιλαμβανει παραγωγα αλκυλ αιθερα ή αλας αυτου | |
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| MY116952A (en) | 4 substituted 2-carboxy-tetrahydroquinoline derivatives, pharmaceutical compositions comprising them and process for their preparation | |
| DK0565377T3 (da) | Terapeutiske midler til behandling af Parkinsons sygdom | |
| RU2010150345A (ru) | Производные хиназолина | |
| ATE381554T1 (de) | Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen | |
| AR015964A1 (es) | Compuestos de isoquinolina, su uso, procedimiento para tratar una afeccion, procedimiento de preparacion del compuesto, composicion farmaceutica que locontiene y compuesto util en dicho procedimiento | |
| MX2009003283A (es) | Nuevos derivados imidazolonas, su preparacion como medicamentos, composiciones farmaceuticas y uso como inhibidores de proteinas quinasas, principalmente cdc7. | |
| HUP0000729A2 (hu) | Új amidszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| UA72919C2 (uk) | Ароматичні аміди, заміщені рибозою, спосіб їх одержання та фармацевтична композиція | |
| PE20001241A1 (es) | Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores |